GlassScriptPhysician profile
Lisa A Dement
NPI 1619918521
$970.32
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.71 · 2022: $497 · 2023: $427 · 2024: $14.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.77 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $108.17 | 2022-2023 | Ingrezza, Ongentys |
| Harmony Biosciences LLC | $104.33 | 2021-2024 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $80.45 | 2022 | |
| Lilly USA, LLC | $75.07 | 2022-2023 | Amyvid |
| Lundbeck LLC | $71.18 | 2022-2023 | Vyepti |
| Pfizer INC. | $60.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $59.70 | 2022-2023 | |
| Sk Life Science, INC. | $43.30 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $39.41 | 2023 | Austedo |
| Emd Serono, INC. | $35.50 | 2023 | Mavenclad |
| Inspire Medical Systems, INC. | $32.84 | 2023 | Inspire |
| Sunovion Pharmaceuticals INC. | $32.03 | 2022 | |
| Argenx US, INC. | $22.43 | 2023 | Vyvgart |
| Avanir Pharmaceuticals, INC. | $21.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $20.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.27 | 2022 | |
| Amgen INC. | $14.50 | 2022 | |
| Axsome Therapeutics, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Dement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.